Lifestyle Modification in Psoriatic Patients With Fatty Liver

Not Applicable

• Conditions: Fatty Liver; Psoriasis
• Interventions: Other: lifestyle modification; Other: usual lifestyle

• Registration Number: NCT05125757
• Lead Sponsor: Cairo University

Brief Summary

Several recent reports have shown an increased prevalence of nonalcoholic fatty liver disease (NAFLD) in those with psoriasis, which may reflect the increased occurrence of metabolic syndrome in this patient population.

Detailed Description

the recruitment of 60 fatty live men with chronic disease, psoriasis, will be classified to lifestyle modification group (foe 12 weeks, this patients will take supervised energy or diet restriction program plus their usual immunosuppressive drugs ) and control group will continue their drug program only)

Study Timeline

• Study Start: 2021-09-13
• Study First Submitted: 2021-10-17
• Status Verified: 2021-11
• Study First Submitted QC: 2021-11-07
• Last Update Submitted: 2021-11-07
• Study First Posted: 2021-11-18
• Last Update Posted: 2021-11-18
• Primary Completion: 2022-03-15
• Study Completion: 2022-03-15

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Male
• Target Recruitment: 60

Inclusion Criteria

• psoriasis obese patients with coexisting fatty liver
• chronic plaque psoriasis
• patients who will not show any change in immuno-modulating psoriasis therapies for at least five months before participation in the study.

Exclusion Criteria

• no metabolic syndrome
• no renal or cardiac or pulmonary disorders
• other types of psoriasis

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
intervention group	lifestyle modification	The patients of this group will receive their usual immuno-modulating therapy plus life style modification (energy or diet restriction in addition to daily walking, 15000 steps)
control group	usual lifestyle	The participants of this group will receive their usual immuno-modulating therapy and continuing their usual diet and activities

Primary Outcome Measures

Name	Time	Method
Psoriasis Area and Severity Index	It will be measured after 12 weeks	it is an index used to measure level and severity of psoriasis

Secondary Outcome Measures

Name	Time	Method
Dermatology Life Quality Index	It will be measured after 12 weeks	it is a questinnaire used to assess life quality in psoriasis humans
triglycerides	It will be measured after 12 weeks	will measured in plasma
BMI	It will be measured after 12 weeks	it is body mass index
ALT	It will be measured after 12 weeks	it is plasma Alanine transaminase
AST	It will be measured after 12 weeks	it is plasma aspartate transaminase
waist circumference	It will be measured after 12 weeks	it will be measured at the level of umbilicus

Trial Locations

Locations (1)

Faculty of Physical Therapy Cairo University; 🇪🇬 Giza, Dokki, Egypt